Basel, 06 October 2017 FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus Zika virus infection is linked to neurological complications in adults, and brain defects in fetuses and newborn infants cobas Zika complements efforts to prevent the spread of Zika virus through blood donations in the U.S. cobas Zika... Read more
Basel, 03 October 2017 Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams The NAVIFY Tumor Board solution is a new, cloud-based software solution that fundamentally changes the way oncology care teams prepare for, conduct and document clinical treatment decisions for cancer patients It supports care team collaboration and standardizes... Read more
Basel, 29 September 2017 FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin®... Read more
Basel, 29 September 2017 FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin®... Read more
Basel, 28 September 2017 Roche’s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis OCREVUS is the first and only approved treatment for people with primary progressive MS, a highly disabling form of MS An important new treatment option for people with relapsing forms of MS demonstrating superior efficacy on... Read more
Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides a new treatment option for people with previously treated locally advanced or metastatic non-small cell cancer (NSCLC) TECENTRIQ is a new treatment option for people with metastatic... Read more
Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides a new treatment option for people with previously treated locally advanced or metastatic non-small cell cancer (NSCLC) TECENTRIQ is a new treatment option for people with metastatic... Read more
Basel, 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which showed superior progression-free survival for Gazyva/Gazyvaro compared to MabThera/Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination... Read more
Basel, 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which showed superior progression-free survival for Gazyva/Gazyvaro compared to MabThera/Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination... Read more
Basel, 22 September 2017 Roche receives European approval for Actemra /RoActemra in giant cell arteritis Actemra/RoActemra is the first therapy approved for the treatment of giant cell arteritis (GCA) in Europe GCA can lead to blindness, aortic aneurysm or stroke if left untreated The approval was based on the outcome of the phase III GiACTA... Read more